Sale

Conjugate Vaccine Market

Global Conjugate Vaccine Market Share, Size, Growth, Report: By Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines; By Indications: Pneumococcal Disease, Influenza, Meningococcal Disease, Others; By Pathogen Type; By Patient Type; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Conjugate Vaccine Market Outlook

The global conjugate vaccine market size attained a value of USD 17.76 billion in 2023 driven by increasing scientific research and the rising demand for meningococcal vaccine. The market is anticipated to grow at a CAGR of 11% during the forecast period of 2024-2032 to attain a value of USD 45.43 billion by 2032.

 

Global Conjugate Vaccine Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Favourable Initiatives by Governments and Organisations Across the Globe Augmenting the Market Growth

The governments of various countries are introducing favourable schemes and programs to accelerate and promote conjugate vaccination in their countries. This is also propelling the market growth. For instance, the Indian government rolled out an anti-pneumonia vaccine as a part of its Universal Immunisation Program. Moreover, countries like the Democratic Republic of Congo, Pakistan, and Nigeria account for the highest death rate of people with pneumonia under the age of five years. Hence, various non-profit organisations are rolling out vaccination drives while raising awareness regarding preventable diseases in the regions. This is anticipated to fuel the market growth for conjugate vaccine.

Pneumonia is one of the dominant causes of child death worldwide. The rising demand to prevent pneumonia and acute respiratory infections is aiding the market growth. Various benefits associated with conjugate vaccines are also increasing their use. They can not only easily result in herd immunity but also have an excellent safety record. Moreover, they improve immunity and memory while providing long-lasting protection. This is increasing the demand for pneumococcal vaccines that aids in the prevention of pneumonia, especially in emerging economies. As pneumococcal conjugate vaccines are suitable for major age groups, their demand is increasing, which, in turn, is invigorating the market growth.

 

Conjugate Vaccine: Market Segmentation

A conjugated vaccine is a vaccine that is composed of weak antigens and a protein carrier molecule. It enhances the immune system and improves antigen’s immunogenicity. It also reduces asymptomatic carriage of the bacteria. Moreover, the vaccine is effective for a long period of time without resulting in any major side effects.

 

Global Conjugate Vaccine Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The major types of conjugate vaccine are:

  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine

The market can be broadly categorised on the basis of its disease indication into:

  • Pneumococcal
  • Influenza
  • Diphtheria Tetanus and Pertussis (DTP)
  • Meningococcal
  • Others

Based on pathogen type, the market is divided into:

  • Bacterial Conjugate Vaccine
  • Viral Conjugate Vaccine
  • Combined Conjugate Vaccine

On the basis of patient, the market is segmented into:

  • Adults
  • Paediatrics

The EMR report looks into the regional markets of conjugate vaccine like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Conjugate Vaccine Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Demand for Meningococcal Vaccine to Bolster the Market Growth for Conjugate Vaccine

According to the World Health Organisation (WHO), meningococcal meningitis, the bacterial form of meningitis, is prevalent in sub-Saharan Africa ranging from Senegal in the west to Ethiopia in the east. As it occurs in the region each year between December and June, various organisations and governments are rolling out vaccination drives in the region. This is increasing the use of meningococcal vaccine, hence augmenting the market growth. Moreover, the launch of various immunisation programs to generate awareness regarding the benefits of conjugate vaccines is providing further impetus to the market growth.

The exponential rise in population is expected to increase the demand for various vaccines, especially among children. The rising attempts of various non-profit organisations for approvals of conjugate vaccines are increasing its demand, hence augmenting the market growth. Increasing scientific research to develop more efficient vaccines is further invigorating the market growth. In addition, the surge of novel pathogens, which can potentially cause severe illnesses, are anticipated to propel the growth of the conjugate vaccine industry in the forecast period. Moreover, the rising demand for diphtheria, pertussis, and tetanus vaccines among children to prevent complications is also catalysing the market growth, therefore significantly contributing to the overall industry growth.

 

Key Industry Players in the Global Conjugate Vaccine Market

The report presents a detailed analysis of the following key players in the global conjugate vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Serum Institute of India Pvt., Ltd.
  • Groupe Sanofi
  • Pfizer Inc. 
  • Novartis AG
  • Bharat Biotech Ltd.
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Indications
  • Pathogen Type
  • Patient Type
  • End User
  • Region
Breakup by Type
  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccines
Breakup by Indications
  • Pneumococcal Disease
  • Influenza
  • Meningococcal Disease
  • Diphtheria Tetanus and Pertussis (DTP)
  • Others
Breakup by Pathogen Type
  • Bacterial Conjugate Vaccine
  • Viral Conjugate Vaccine
  • Combination (Viral and Bacterial)
Breakup by Patient Type
  • Pediatrics
  • Adults
Breakup by End User
  • Hospitals
  • Clinics
  • Homecare Settings
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Merck & Co., Inc.
  • Novartis AG
  • Serum Institute of India Pvt. Ltd.
  • Pfizer Inc.
  • Sanofi
  • Bharat Biotech
  • Biological E
  • GlaxoSmithKline plc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • SutroVax Inc.
  • CSL Limited
  • Bavarian Nordic
  • Emergent BioSolutions Inc.
  • Valneva SE
  • Moderna, Inc.
  • Novavax
  • Johnson & Johnson Services, Inc.
  • Themis Bioscience GmbH
  • B. Braun Melsungen AG

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Conjugate Vaccines Market Overview 

    3.1    Global Conjugate Vaccines Market Historical Value (2017-2023)
    3.2    Global Conjugate Vaccines Market Forecast Value (2024-2032)
4    Global Conjugate Vaccines Market Landscape
    4.1    Global Conjugate Vaccines Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Conjugate Vaccines Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Indications
        4.2.3    Analysis by Pathogen Type
5    Global Conjugate Vaccines Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Conjugate Vaccines Market Segmentation 
    6.1    Global Conjugate Vaccines Market by Type
        6.1.1    Market Overview
        6.1.2    Monovalent Conjugate Vaccines
        6.1.3    Multivalent Conjugate Vaccines
    6.2    Global Conjugate Vaccines Market by Indications
        6.2.1    Market Overview
        6.2.2    Pneumococcal Disease
        6.2.3    Influenza
        6.2.4    Meningococcal Disease 
        6.2.5    Diphtheria Tetanus and Pertussis (DTP)
        6.2.6    Others
    6.3    Global Conjugate Vaccines Market by Pathogen Type
        6.3.1    Market Overview
        6.3.2    Bacterial Conjugate Vaccine
        6.3.3    Viral Conjugate Vaccine
        6.3.4    Combination (Viral and Bacterial)
    6.4    Global Conjugate Vaccines Market by Patient Type
        6.4.1    Market Overview
        6.4.2    Pediatrics
        6.4.3    Adults
    6.5    Global Conjugate Vaccines Market by End User
        6.5.1    Market Overview
        6.5.2    Hospitals 
        6.5.3    Clinics
        6.5.4    Homecare Settings
        6.5.5    Others
    6.6    Global Conjugate Vaccines Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Conjugate Vaccines Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Conjugate Vaccines Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Conjugate Vaccines Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Conjugate Vaccines Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Conjugate Vaccines Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Clinical Trials Analysis 
    14.1     Analysis by Trial Registration Year 
    14.2    Analysis by Trial Status 
    14.3    Analysis by Trial Phase 
    14.4    Analysis by Therapeutic Area 
    14.5    Analysis by Geography 
15    Funding Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    Merck & Co., Inc.
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Novartis AG
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Serum Institute of India Pvt. Ltd.
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Pfizer Inc.
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Sanofi
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Bharat Biotech
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Biological E
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    GlaxoSmithKline plc.
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Astellas Pharma Inc.
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    AstraZeneca
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    SutroVax Inc.
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    CSL Limited
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Bavarian Nordic
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Emergent BioSolutions Inc.
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
    18.15    Valneva SE
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisitions
        18.15.5    Certifications
    18.16    Moderna, Inc.
        18.16.1    Financial Analysis
        18.16.2    Product Portfolio
        18.16.3    Demographic Reach and Achievements
        18.16.4    Mergers and Acquisitions
        18.16.5    Certifications
    18.17    Novavax
        18.17.1    Financial Analysis
        18.17.2    Product Portfolio
        18.17.3    Demographic Reach and Achievements
        18.17.4    Mergers and Acquisitions
        18.17.5    Certifications
    18.18    Johnson & Johnson Services, Inc.
        18.18.1    Financial Analysis
        18.18.2    Product Portfolio
        18.18.3    Demographic Reach and Achievements
        18.18.4    Mergers and Acquisitions
        18.18.5    Certifications
    18.19    Themis Bioscience GmbH
        18.19.1    Financial Analysis
        18.19.2    Product Portfolio
        18.19.3    Demographic Reach and Achievements
        18.19.4    Mergers and Acquisitions
        18.19.5    Certifications
    18.20    B. Braun Melsungen AG
        18.20.1    Financial Analysis
        18.20.2    Product Portfolio
        18.20.3    Demographic Reach and Achievements
        18.20.4    Mergers and Acquisitions
        18.20.5    Certifications
19    Global Conjugate Vaccines Market - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for conjugate vaccine reached a value of USD 17.76 billion.

The market is anticipated to grow at a CAGR of 11% during the forecast period of 2024-2032 to reach a value of USD 45.43 billion by 2032.

The industry is being driven by favourable government initiatives and the rising attempts to prevent pneumonia—related deaths.

The market is expected to be driven by the increasing scientific research and the rising demand for meningococcal vaccine.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major types of conjugate vaccine in the industry are monovalent conjugate vaccine and multivalent conjugate vaccine.

The significant disease indications in the market are pneumococcal, influenza, diphtheria tetanus and pertussis (DTP), and meningococcal, among others.

The leading pathogen types of conjugate vaccine are bacterial conjugate vaccine, viral conjugate vaccine, and combined conjugate vaccine.

The dominant patients of conjugate vaccine are adults and paediatrics.

The major players in the industry are Serum Institute of India Pvt., Ltd., Groupe Sanofi, Pfizer Inc., Novartis AG, and Bharat Biotech Ltd., among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER